ALL BLOGS BY

Kate Legge

Kate is an experienced IP and patent lawyer, providing IP leadership for pharmaceutical product development and commercialisation in global markets – from initial scoping through to post-launch. She has developed and implemented global IP strategies over more than 15 years at multi-national pharmaceutical companies. She is an Australian qualified and registered legal practitioner, and has a Master’s degree in IP Law and a BSc in biochemistry.

See Kate's full profile

Medicinal Cannabis in Australia | Part 5: Making therapeutic claims: advertising and labelling of medicinal cannabis products

by Kate Legge, Katrina Crooks | May 17, 2022

Introduction The promotion of medicinal cannabis products presents some specific challenges given that very few such...

Medicinal Cannabis in Australia | Part 2: Patient access via the Special Access Scheme (SAS) and Authorised Prescriber (AP) pathways

by Kate Legge, Emily Bristow, Naomi Pearce | May 10, 2022

Introduction As noted in part 1 of our blog series, the vast majority of medicinal cannabis products are not...

Pharmacia’s Dynastat patent expires before injunction ordered; but validity challenge means section 19 certification is still issued

by Katrina Crooks, Kate Legge | Apr 20, 2022

We recently reported on the decision in Pharmacia LLC v Juno Pharmaceuticals Pty Ltd [2022] FCA 92 in which the...

The Full Federal Court overturns AI inventorship in Australia

by Grant Shoebridge PhD, Kate Legge | Apr 19, 2022

An enlarged bench of the Full Court of the Federal Court has overturned a first instance decision, reported here, by...

Patent litigation in Australia just got a little cheaper

Full Court confirms duplicative expert evidence legitimately excluded on discretionary grounds

by Naomi Pearce, Katrina Crooks, Kate Legge | Apr 8, 2022

The Full Court’s refusal of leave to appeal today in Novartis AG v Pharmacor Pty Limited [2022] FCAFC 58 is good news...

Pharmacia’s Dynastat patent valid, imminent patent expiry no reason to avoid injunction

by Katrina Crooks, Kate Legge | Mar 21, 2022

Introduction Pharmacia LLC and Pfizer Australia Pty Ltd (together, Pharmacia) have partially succeeded at first...

PTE alert: Patent Office cancellation of PTE paves the way for potential launch of generic YASMIN products

by Katrina Crooks, Kate Legge | Feb 15, 2022

We have previously reported on a number of Federal Court decisions in 2021 invalidating patent term extensions (PTEs)...

Comments period on draft new National Medicines Policy extended – now closing on 2 March

by Naomi Pearce, Kate Legge | Feb 7, 2022

Last week we alerted you to the release of a draft new National Medicines Policy (NMP) for public comment. The draft...

No time to lose! Comments on the consultation draft of the new National Medicines Policy close on 16 February

by Naomi Pearce, Kate Legge | Feb 3, 2022

On 2 February a draft of a new National Medicines Policy (NMP) was made available for public comment. The draft NMP...

To waive or not to waive: that is the question

Will IP waivers have any impact on COVID-19 vaccine rollouts?

by Kate Legge, Jennifer Enmon PhD, Emily Bristow | May 12, 2021

IP waivers alone are nowhere near enough to increase COVID-19 vaccine access for developing countries, but US support...

The COVID-19 pandemic prioritises an Australian medical products’ manufacturing road map

by Grant Shoebridge PhD, Kate Legge | Mar 25, 2021

Background In October 2020, the Australian Government announced a $1.5 billion investment in a Modern Manufacturing...